scholarly journals Repetitive transcranial magnetic stimulation treatment for depressive disorders

2019 ◽  
Vol 32 (5) ◽  
pp. 409-415 ◽  
Author(s):  
Chris Baeken ◽  
Anna-Katharine Brem ◽  
Martijn Arns ◽  
Andre R. Brunoni ◽  
Igor Filipčić ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Repetitive Transcranial Magnetic Stimulation

The Use of Repetitive Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder: A Scoping Review. (Preprint)

2021 ◽  
Author(s):  
Medard Adu ◽  
Ejemai Eboreime ◽  
Adegboyega Sapara ◽  
Andrew J. Greenshaw ◽  
Pierre Chue ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Obsessive Compulsive Disorder ◽  
Scoping Review ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Relevant Literature ◽  
Invasive Procedure ◽  
Obsessive Compulsive ◽  
Compulsive Disorder

BACKGROUND Background: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive procedure in which brain neural activity is stimulated by direct application of a magnetic field to the scalp. rTMS is considered a therapeutic tool in various neuropsychiatric conditions. Since its approval in Canada in 2002 and despite its wide and continuous usage for the management of depressive disorders, knowledge on the use of rTMS for Obsessive-Compulsive Disorder (OCD) is sparse. OBJECTIVE Objectives: This scoping review seeks to; (i) explore the relevant literature available regarding the use of rTMS as a mode of treatment for OCD; (ii) To evaluate the evidence to support the use of rTMS as a treatment option for OCD. METHODS Method: We electronically conducted data search in five research databases (MEDLINE, CINAHL, Psych INFO, SCOPUS, and EMBASE) using all identified keywords and index terms across all the data bases to identify empirical studies and randomized controlled trials. We included articles published with randomized control designs which aimed at the treatment of OCD with rTMS. Only full-text published articles written in English were reviewed. Review articles on treatment for conditions other than OCD were excluded. RESULTS NA CONCLUSIONS Conclusion: The application of rTMS as a treatment intervention for OCD looks promising despite diversity in terms of outcomes and clinical significance. Further studies with well-defined stimulation parameters are needed in order to be able to draw a definite conclusion of its clinical effectiveness in the treatment of OCD.

How Does Repetitive Transcranial Magnetic Stimulation Influence the Brain in Depressive Disorders?

2018 ◽  
Vol 34 (2) ◽  
pp. 79-86 ◽  
Author(s):  
Simon Taïb ◽  
Christophe Arbus ◽  
Anne Sauvaget ◽  
Marie Sporer ◽  
Laurent Schmitt ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
The Brain

scholarly journals Meta-Review of Metanalytic Studies with Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depression

2011 ◽  
Vol 7 (1) ◽  
pp. 167-177 ◽  
Author(s):  
Bernardo Dell’Osso ◽  
Giulia Camuri ◽  
Filippo Castellano ◽  
Vittoria Vecchi ◽  
Matteo Benedetti ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Major Depression ◽  
Brain Stimulation ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Effective Parameters ◽  
Duration Of Treatment ◽  
Meta Analyses ◽  
Stimulation Technique

Background:Major Depression (MD) and treatment-resistant depression (TRD) are worldwide leading causes of disability and therapeutic strategies for these impairing and prevalent conditions include pharmacological augmentation strategies and brain stimulation techniques. In this perspective, repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique with a favorable profile of tolerability which, despite being recently approved by the Food and Drug Administration (FDA) for the treatment of patients with medication-refractory unipolar depression, still raises some doubts about most effective parameters of stimulation.Methods:A literature search was performed using PubMed for the years 2001 through February 2011 in order to review meta-analytic studies assessing efficacy and safety issues for rTMS in depressive disorders. Fifteen meta-analyses were identified and critically discussed in order to provide an updated and comprehensive overview of the topic with specific emphasis on potentially optimal parameters of stimulation.Results:First meta-analyses on the efficacy of rTMS for the treatment of MD and TRD have shown mixed results. On the other hand, more recent meta-analytic studies seem to support the antidepressant efficacy of the technique to a greater extent, also in light of longer periods of stimulation (e.g. > 2 weeks).Conclusion:rTMS seems to be an effective and safe brain stimulation technique for the treatment of medication refractory depression. Nevertheless, further studies are needed to better define specific stimulation-related issues, such as duration of treatment as well as durability of effects and predictors of response.

Comparative Efficacy and Acceptability of 3 Repetitive Transcranial Magnetic Stimulation Devices for Depression: A Meta-Analysis of Randomized, Sham-Controlled Trials

2021 ◽  
pp. 1-9
Author(s):  
Yuki Matsuda ◽  
Ryuichi Yamazaki ◽  
Taro Kishi ◽  
Nakao Iwata ◽  
Masahiro Shigeta ◽  
...  
Keyword(s):  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Remission Rate ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Meta Analysis ◽  
Similar Efficacy ◽  
Controlled Trials ◽  
Resistant Depression ◽  
Therapy Resistant Depression

<b><i>Introduction:</i></b> Repetitive transcranial magnetic stimulation (rTMS) has been employed worldwide for therapy-resistant depression. The Food and Drug Administration has approved a number of therapeutic devices for treating major depressive disorder; however, no studies have examined the differences in efficacy and acceptability among commercially available stimulation devices. The aim of our study was to compare the efficacy and acceptability of 3 stimulation devices (NeuroStar, MagPro, and Magstim) for depressive disorders. <b><i>Methods:</i></b> Our study included 31 randomized sham-controlled trials of high-frequency rTMS included in the network meta-analysis by Brunoni. We calculated the risk ratio and 95% confidence intervals, comparing each device with sham for the endpoints of response rate, remission rate, and all-cause discontinuation. We then analyzed the differences among the devices in effect size for those endpoints. <b><i>Results:</i></b> After determining the effect sizes for the endpoints, we found no statistically significant subgroup differences in the response rates, all-cause discontinuation, or remission rates among the devices (<i>p</i> = 0.12, <i>p</i> = 0.84, and <i>p</i> = 0.07, respectively). <b><i>Conclusion:</i></b> Our results suggest similar efficacy and acceptability for the 3 stimulation devices. Future studies need to perform head-to-head comparisons of the efficacy and acceptability of the stimulation devices for treating depression using the same stimulation protocols.

Is it Time to Introduce Repetitive Transcranial Magnetic Stimulation into Standard Clinical Practice for the Treatment of Depressive Disorders?

2003 ◽  
Vol 37 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Paul Fitzgerald
Keyword(s):  
Clinical Practice ◽  
Transcranial Magnetic Stimulation ◽  
Magnetic Stimulation ◽  
Depressive Disorders ◽  
Repetitive Transcranial Magnetic Stimulation ◽  
Basic Research ◽  
Early Introduction ◽  
Standard Clinical Practice ◽  
New Treatment ◽  
Clinical Research Trials

Objective: To examine issues relating to the potential introduction of repetitive transcranial magnetic stimulation (rTMS) into clinical practice as a treatment for depression. Method: A review of the outcomes literature accompanied by an analysis of issues relating to the potential advantages and pitfalls of the introduction of rTMS as a treatment strategy. Results: Evidence is progressively accumulating that rTMS has antidepressant properties that are clinically relevant. These effects are biologically plausible and supported by basic research. Patients with therapy-resistant depression have few treatment alternatives and experience significant suffering, thus justifying the early introduction of a new treatment such as rTMS for this patient group. However, this must be balanced by a need to foster considerable further research and not to raise expectations unreasonably. Conclusions: It is timely for rTMS to be made more available to patients with treatment-resistant mood disorders. This need not be limited to clinical research trials but should only occur in medical settings where continual evaluation and research is conducted.

Sign in / Sign up

Export Citation Format

Share Document